154 related articles for article (PubMed ID: 36070964)
1. Prediction of the final menstrual period in women taking Dienogest using estradiol and follicle-stimulating hormone values: a case-control study.
Uehara M; Wada-Hiraike O; Koga K; Yamamoto N; Hirano M; Harada M; Hirota Y; Osuga Y
Endocr J; 2022 Dec; 69(12):1437-1445. PubMed ID: 36070964
[TBL] [Abstract][Full Text] [Related]
2. Pelvic pain and quality of life of women with endometriosis during quadriphasic estradiol valerate/dienogest oral contraceptive: a patient-preference prospective 24-week pilot study.
Grandi G; Xholli A; Napolitano A; Palma F; Cagnacci A
Reprod Sci; 2015 May; 22(5):626-32. PubMed ID: 25394646
[TBL] [Abstract][Full Text] [Related]
3. Serum follicle stimulating hormone and estradiol in peri/postmenopausal women attending Siriraj Menopause Clinic: a retrospective study.
Angsuwathana S; Tanmahasamut P; Rattanachaiyanont M; Dangrat C; Techatrisak K; Indhavivadhana S; Leerasiri P
J Med Assoc Thai; 2006 Aug; 89(8):1101-8. PubMed ID: 17048416
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of dienogest versus gonadotropin-releasing hormone agonist combined with dienogest sequential therapy in the treatment of adenomyosis].
Zhang HY; Zhu S; Xu W; Wang AQ; Wang XL
Zhonghua Fu Chan Ke Za Zhi; 2022 Nov; 57(11):856-863. PubMed ID: 36456483
[No Abstract] [Full Text] [Related]
5. Compare the Efficacy of Dienogest and the Levonorgestrel Intrauterine System in Women with Adenomyosis.
Guo W; Lin Y; Hu S; Shen Y
Clin Ther; 2023 Oct; 45(10):973-976. PubMed ID: 37599165
[TBL] [Abstract][Full Text] [Related]
6. Effect of a contraceptive pill containing estradiol valerate and dienogest (E2V/DNG) in women with menstrually-related migraine (MRM).
Nappi RE; Terreno E; Sances G; Martini E; Tonani S; Santamaria V; Tassorelli C; Spinillo A
Contraception; 2013 Sep; 88(3):369-75. PubMed ID: 23453784
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the safety of dienogest in women with adenomyosis: A retrospective analysis.
Ono N; Asano R; Nagai K; Sugo Y; Nakamura T; Miyagi E
J Obstet Gynaecol Res; 2021 Apr; 47(4):1433-1440. PubMed ID: 33590656
[TBL] [Abstract][Full Text] [Related]
8. Pituitary-ovarian relationships preceding the menopause. I. A cross-sectional study of serum follice-stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone levels.
Reyes FI; Winter JS; Faiman C
Am J Obstet Gynecol; 1977 Nov; 129(5):557-64. PubMed ID: 910845
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for non-response and discontinuation of Dienogest in endometriosis patients: A cohort study.
Nirgianakis K; Vaineau C; Agliati L; McKinnon B; Gasparri ML; Mueller MD
Acta Obstet Gynecol Scand; 2021 Jan; 100(1):30-40. PubMed ID: 32767677
[TBL] [Abstract][Full Text] [Related]
10. Risk factors of heavy uterine bleeding in patients with endometriosis and adenomyosis treated with dienogest.
Takagi H; Takakura M; Sasagawa T
Taiwan J Obstet Gynecol; 2023 Nov; 62(6):852-857. PubMed ID: 38008504
[TBL] [Abstract][Full Text] [Related]
11. Estradiol Valerate vs Ethinylestradiol in Combined Oral Contraceptives: Effects on the Pituitary-Ovarian Axis.
Haverinen A; Luiro K; Kangasniemi MH; Piltonen TT; Hustad S; Heikinheimo O; Tapanainen JS
J Clin Endocrinol Metab; 2022 Jun; 107(7):e3008-e3017. PubMed ID: 35279718
[TBL] [Abstract][Full Text] [Related]
12. Use of dienogest over 53 weeks for the treatment of endometriosis.
Sugimoto K; Nagata C; Hayashi H; Yanagida S; Okamoto A
J Obstet Gynaecol Res; 2015 Dec; 41(12):1921-6. PubMed ID: 26369271
[TBL] [Abstract][Full Text] [Related]
13. Differences in hormonal patterns during the first postabortion menstrual cycle after two techniques of termination of pregnancy.
Blazar AS; Harlin J; Zaidi AA; Diczfalusy E
Fertil Steril; 1980 May; 33(5):493-500. PubMed ID: 6768597
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment of dienogest with symptomatic adenomyosis: retrospective analysis of efficacy and safety in clinical practice.
Miao J; Lu J; Tang J; Lu P
Gynecol Endocrinol; 2022 Aug; 38(8):656-660. PubMed ID: 35850637
[No Abstract] [Full Text] [Related]
15. Laboratory criteria for menopause in women using oral contraceptives.
Creinin MD
Fertil Steril; 1996 Jul; 66(1):101-4. PubMed ID: 8752618
[TBL] [Abstract][Full Text] [Related]
16. Proposal for developing treatment algorithms of women with symptomatic adenomyosis: A single-center experience.
Kobayashi H; Imanaka S
J Obstet Gynaecol Res; 2021 Sep; 47(9):3257-3268. PubMed ID: 34155744
[TBL] [Abstract][Full Text] [Related]
17. A cohort study of the efficacy of the dienogest and the gonadotropin-releasing hormone agonist in women with adenomyosis and dysmenorrhea.
Ji M; Yuan M; Jiao X; Li Q; Huang Y; Li J; Wang G
Gynecol Endocrinol; 2022 Feb; 38(2):164-169. PubMed ID: 34749585
[TBL] [Abstract][Full Text] [Related]
18. Estradiol and Follicle-Stimulating Hormone as Predictors of Onset of Menopause Transition-Related Bone Loss in Pre- and Perimenopausal Women.
Shieh A; Greendale GA; Cauley JA; Karvonen-Gutierrez C; Crandall CJ; Karlamangla AS
J Bone Miner Res; 2019 Dec; 34(12):2246-2253. PubMed ID: 31442329
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Adenomyosis with Subcutaneous Etonogestrel Implants: A Clinical Observational Study in 17 Patients.
Wu J; Huang Y; Chen L; Hu J; Zou Y
Med Sci Monit; 2018 Sep; 24():6085-6092. PubMed ID: 30171680
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of gonadotropin-releasing hormone agonist and an extended-interval dosing regimen in the treatment of patients with adenomyosis and endometriosis.
Kang JL; Wang XX; Nie ML; Huang XH
Gynecol Obstet Invest; 2010; 69(2):73-7. PubMed ID: 19923847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
